Search

Genmab A-S

Открыт

2,298 0.66

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

2238

Макс.

2314

Ключевые показатели

By Trading Economics

Доход

243M

295M

Продажи

259M

1.2B

P/E

Средняя по отрасли

27.397

55.725

Прибыль на акцию

34.85

Рентабельность продаж

25.541

Сотрудники

3,119

EBITDA

216M

431M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-1.49% downside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

26B

139B

Предыдущая цена открытия

2297.34

Предыдущая цена закрытия

2298

Genmab A-S График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

22 сент. 2026 г., 23:56 UTC

Correlated Moves

TE Connectivity PLC declined slightly in after-market trading, amid concerns over economic momentum following a drop in the Richmond Fed Manufacturing Index.

22 сент. 2026 г., 23:56 UTC

Raymond James Financial Inc is trading modestly lower in after-market hours, continuing a decline since Tuesday and remaining near the low end of its one-month range.

22 сент. 2026 г., 23:56 UTC

Correlated Moves

Hess Midstream LP is trading lower in after-market hours, following a flat session and amid a decline in shares of Targa Resources Corp.

22 сент. 2026 г., 23:56 UTC

Correlated Moves

Agree Realty Corp is trading slightly higher in after-market hours, influenced by positive earnings reports from consumer discretionary companies.

22 сент. 2026 г., 23:56 UTC

Plumas Bancorp remains roughly flat in after-market trading, showing little change since Tuesday's close and oscillating around the midpoint of its one-month trading range.

22 сент. 2026 г., 23:56 UTC

Correlated Moves

Delek US Holdings Inc is trading lower in after-market hours, potentially in sympathy with HF Sinclair Corp, which has also declined.

22 сент. 2026 г., 23:55 UTC

Andersons Inc is experiencing notable gains in after-market trading, recovering from previous lower closes but remains below its 20-day moving average.

22 сент. 2026 г., 23:55 UTC

Pentair PLC is trading modestly higher in after-market hours, continuing a gradual increase, though it remains below its 20-day moving average.

22 сент. 2026 г., 23:55 UTC

Healthequity Inc. is trading modestly lower in after-market hours, continuing a decline from Tuesday's close and remaining below its 20-day moving average.

22 сент. 2026 г., 23:55 UTC

M&T Bank Corp is trading modestly higher in after-market hours, remaining above its opening level despite a slight pullback during the regular session.

22 сент. 2026 г., 23:55 UTC

Darling Ingredients Inc is trading modestly lower in after-market hours, continuing a four-session decline and remaining significantly below its 20-day moving average.

22 сент. 2026 г., 23:55 UTC

News

Roivant Sciences Ltd is higher in after-market trading following positive Phase 2 trial results for mosliciguat, showing significant improvements in pulmonary hypertension patients.

22 сент. 2026 г., 23:52 UTC

CarMax Inc. is trading modestly lower in after-market hours, continuing a decline since Tuesday's close and remaining below its 20-day moving average.

22 сент. 2026 г., 23:51 UTC

News

Itron Inc's stock is declining in after-market trading, despite the launch of its Riva IEC Grid Edge Portfolio in the Asia Pacific region.

22 сент. 2026 г., 23:51 UTC

MACOM Technology Solutions Holdings Inc is up in after-market trading, continuing a trend of seven consecutive higher daily closes and remaining above its 20-day moving average.

22 сент. 2026 г., 23:51 UTC

Old Dominion Freight Line Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a brief rise earlier.

22 сент. 2026 г., 23:51 UTC

First Solar Inc is trading modestly lower in after-market hours, following a notable dip earlier in the session and remaining below its 20-day moving average.

22 сент. 2026 г., 23:51 UTC

Eversource Energy is trading modestly higher in after-market hours, despite recent lower performance and positioning below its 20-day moving average.

22 сент. 2026 г., 23:51 UTC

Nucor Corp is trading modestly lower in after-market hours, continuing a downward trend since Tuesday's close and positioned below its 20-day moving average.

22 сент. 2026 г., 23:51 UTC

Targa Resources Corp is seeing a modest decline in after-market trading, continuing a trend of three consecutive lower daily closes.

22 сент. 2026 г., 23:51 UTC

Correlated Moves

SM Energy Co is trading modestly lower in after-market hours, continuing a decline amid concerns from the Richmond Fed Manufacturing Index's unexpected fall.

22 сент. 2026 г., 23:51 UTC

Brazil's Unemployment Rate Set to Release on September 29, Expected to Reflect Continued Labor Market Improvement Amid Global Economic Concerns.

22 сент. 2026 г., 23:51 UTC

Australia's S&P Global Services PMI at 51.4 signals slight expansion, but mixed retail forecasts raise concerns about consumer spending ahead of the holiday season.

22 сент. 2026 г., 23:51 UTC

Australia's S&P Global Manufacturing PMI Flash at 49.3 Signals Contraction, Raising Concerns Over Economic Growth and Potential Monetary Policy Adjustments.

22 сент. 2026 г., 23:51 UTC

Japan's Industrial Production Report Set for Release on September 29, Amidst Positive Trends and Global Economic Influences.

22 сент. 2026 г., 23:51 UTC

Japan's Retail Sales Data Release on September 29 Faces Caution Amid Interest Rate Hike and Yen Weakness.

22 сент. 2026 г., 23:50 UTC

News

Coeur Mining plans a record $158 million exploration investment for 2026, more than double 2025's budget, as shares rise in after-market trading.

22 сент. 2026 г., 23:50 UTC

Cinemark Holdings Inc is declining in after-market trading, falling from earlier gains and nearing the lower end of its one-month trading range.

22 сент. 2026 г., 23:50 UTC

Veeva Systems Inc is trading modestly higher in after-hours action, remaining below its 20-day moving average and around the midpoint of its one-month range.

22 сент. 2026 г., 23:50 UTC

Aspen Aerogels Inc is trading lower in after-market hours, showing a significant decline from Tuesday's close, though still above its 20-day moving average.

Сравнение c конкурентами

Изменение цены

Genmab A-S Прогноз

Целевая цена

By TipRanks

-1.49% падение

Прогноз на 12 месяцев

Средняя 2,493.35 DKK  -1.49%

Максимум 3,320 DKK

Минимум 308.417 DKK

Основано на мнении 7 аналитиков Wall Street, спрогнозировавших целевые цены для Genmab A-S на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

7 ratings

3

Покупка

2

Удержание

2

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.